Juha Grönholm1, Philippe P Pagni2,3, Minh N Pham2, Claire B Gibson2, Paul F Macomber4, José Luis Vela2, Matthias von Herrath2, Michael J Lenardo5. 1. Molecular Development of the Immune System Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases (NIAID) and Clinical Genomics Program, NIAID, National Institutes of Health, Building 10, Room 11D14, 10 Center Drive, Bethesda, MD, 20814, USA. 2. Novo Nordisk Type 1 Diabetes Center, Novo Nordisk Research Center, Seattle, WA, USA. 3. La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA. 4. Wellstat Diagnostics, Gaithersburg, MD, USA. 5. Molecular Development of the Immune System Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases (NIAID) and Clinical Genomics Program, NIAID, National Institutes of Health, Building 10, Room 11D14, 10 Center Drive, Bethesda, MD, 20814, USA. lenardo@nih.gov.
Abstract
AIMS/HYPOTHESIS: Insulin is widely considered to be a driver antigen in type 1 diabetes in humans and in mouse models of the disease. Therefore, insulin or insulin analogues are candidates for tolerogenic drugs to prevent disease onset in individuals with risk of diabetes. Previous experiments have shown that autoimmune diabetes can be prevented in NOD mice by repeated doses of insulin administered via an oral, nasal or parenteral route, but clinical trials in humans have not succeeded. The hypoglycaemic activity of insulin is dose-limiting in clinical studies attempting tolerance and disease prevention. Here, we aimed to investigate the therapeutic potential of metabolically inactive insulin analogue (MII) in NOD mice. METHODS: The tolerogenic potential of MII to prevent autoimmune diabetes was studied by administering multiple i.v. or s.c. injections of MII to non-diabetic 7-12-week-old female NOD mice in three geographical colony locations. The incidence of diabetes was assessed from daily or weekly blood glucose measurements. The effect of MII on insulin autoantibody levels was studied using an electrochemiluminescence-based insulin autoantibody assay. The effect on the number of insulin-reactive CD8+ and CD4+ T lymphocytes in peripheral lymphoid tissue was studied with MHC class I and MHC class II tetramers, respectively. RESULTS: We found that twice-weekly s.c. administration of MII accelerates rather than prevents diabetes. High-dose i.v. treatment did not prevent disease or affect insulin autoantibody levels, but it increased the amount of insulin-reactive CD4+ T lymphocytes in peripheral lymphoid tissue. CONCLUSIONS/ INTERPRETATION: Our data suggest that parenteral MII, even when used in high doses, has little or no therapeutic potential in NOD mice and may exacerbate disease.
AIMS/HYPOTHESIS: Insulin is widely considered to be a driver antigen in type 1 diabetes in humans and in mouse models of the disease. Therefore, insulin or insulin analogues are candidates for tolerogenic drugs to prevent disease onset in individuals with risk of diabetes. Previous experiments have shown that autoimmune diabetes can be prevented in NOD mice by repeated doses of insulin administered via an oral, nasal or parenteral route, but clinical trials in humans have not succeeded. The hypoglycaemic activity of insulin is dose-limiting in clinical studies attempting tolerance and disease prevention. Here, we aimed to investigate the therapeutic potential of metabolically inactive insulin analogue (MII) in NOD mice. METHODS: The tolerogenic potential of MII to prevent autoimmune diabetes was studied by administering multiple i.v. or s.c. injections of MII to non-diabetic 7-12-week-old female NOD mice in three geographical colony locations. The incidence of diabetes was assessed from daily or weekly blood glucose measurements. The effect of MII on insulin autoantibody levels was studied using an electrochemiluminescence-based insulin autoantibody assay. The effect on the number of insulin-reactive CD8+ and CD4+ T lymphocytes in peripheral lymphoid tissue was studied with MHC class I and MHC class II tetramers, respectively. RESULTS: We found that twice-weekly s.c. administration of MII accelerates rather than prevents diabetes. High-dose i.v. treatment did not prevent disease or affect insulin autoantibody levels, but it increased the amount of insulin-reactive CD4+ T lymphocytes in peripheral lymphoid tissue. CONCLUSIONS/ INTERPRETATION: Our data suggest that parenteral MII, even when used in high doses, has little or no therapeutic potential in NOD mice and may exacerbate disease.
Authors: Lisl K M Shoda; Daniel L Young; Saroja Ramanujan; Chan C Whiting; Mark A Atkinson; Jeffrey A Bluestone; George S Eisenbarth; Diane Mathis; Aldo A Rossini; Scott E Campbell; Richard Kahn; Huub T C Kreuwel Journal: Immunity Date: 2005-08 Impact factor: 31.745
Authors: A Vølund; J Brange; K Drejer; I Jensen; J Markussen; U Ribel; A R Sørensen; J Schlichtkrull Journal: Diabet Med Date: 1991-11 Impact factor: 4.359
Authors: Maki Nakayama; Norio Abiru; Hiroaki Moriyama; Naru Babaya; Edwin Liu; Dongmei Miao; Liping Yu; Dale R Wegmann; John C Hutton; John F Elliott; George S Eisenbarth Journal: Nature Date: 2005-05-12 Impact factor: 49.962
Authors: L Chaillous; H Lefèvre; C Thivolet; C Boitard; N Lahlou; C Atlan-Gepner; B Bouhanick; A Mogenet; M Nicolino; J C Carel; P Lecomte; R Maréchaud; P Bougnères; B Charbonnel; P Saï Journal: Lancet Date: 2000-08-12 Impact factor: 79.321
Authors: A Muir; A Peck; M Clare-Salzler; Y H Song; J Cornelius; R Luchetta; J Krischer; N Maclaren Journal: J Clin Invest Date: 1995-02 Impact factor: 14.808
Authors: James F Mohan; Matteo G Levisetti; Boris Calderon; Jeremy W Herzog; Shirley J Petzold; Emil R Unanue Journal: Nat Immunol Date: 2010-02-28 Impact factor: 25.606